Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | PTAFR | P25105 | 1/20 | 0.53 |
| ▸ | HTR1D | P28221 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.53 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27795601 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL1008410 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL2732833 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL7411764 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL1009136 | 1.00 | PRKCA (0.65) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL9436412 | 0.98 | PRKCA (0.62) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL4324597 | 0.93 | PRKCA (0.59) | PRKCAUSP2ADRA1DPTAFRHTR1D | |
| SCHEMBL4912502 | 0.91 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL4912512 | 0.91 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT | |
| SCHEMBL1000470 | 0.91 | PRKCA (0.62) | PRKCAPRKCEPRKCQPRKCDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | NASTECH PHARMACEUTICAL COMPANY INC. | 2007-04-05 | — | — | US | disclosed |
| US-4595681-A | Administering neutral glycerolipid | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070077283-A1 | METHOD OF ENHANCING TRANSMUCOSAL DELIVERY OF THERAPEUTIC COMPOUNDS | PGF, PLAT, PTAFR | PRKCA 1613/4885USP2 3125/4885ADRA1D 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.